^
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
PD-L1 expression
|
Oral Cancer
|
PD-L1 expression
|
Oral Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
|
cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
nivolumab Sensitive: A2 - Guideline
|
nivolumab Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
methotrexate Sensitive: A2 - Guideline
|
methotrexate Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cisplatin + docetaxel Sensitive: A2 - Guideline
|
cisplatin + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cetuximab Sensitive: A2 - Guideline
|
cetuximab Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
afatinib Sensitive: A2 - Guideline
|
afatinib Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
5-fluorouracil Sensitive: A2 - Guideline
|
5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cisplatin Sensitive: A2 - Guideline
|
cisplatin Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A2 - Guideline
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
cisplatin + paclitaxel Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
cisplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
5-fluorouracil + hydroxyurea Sensitive: A2 - Guideline
|
5-fluorouracil + hydroxyurea Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
carboplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
carboplatin + 5-fluorouracil Sensitive: A2 - Guideline
|
No biomarker
|
Oral Cancer
|
No biomarker
|
Oral Cancer
|
pembrolizumab + cetuximab Sensitive: A2 - Guideline
|
pembrolizumab + cetuximab Sensitive: A2 - Guideline
|
GDF15 overexpression
|
Oral Cancer
|
GDF15 overexpression
|
Oral Cancer
|
TPF Sensitive: C3 – Early Trials
|
TPF Sensitive: C3 – Early Trials
|
POU5F1 overexpression + NANOG overexpression
|
Oral Cancer
|
POU5F1 overexpression + NANOG overexpression
|
Oral Cancer
|
cisplatin Resistant: C3 – Early Trials
|
cisplatin Resistant: C3 – Early Trials
|
miR-1290-L
|
Oral Cancer
|
miR-1290-L
|
Oral Cancer
|
5-fluorouracil Sensitive: C3 – Early Trials
|
5-fluorouracil Sensitive: C3 – Early Trials
|
KRAS mutation
|
Oral Cancer
|
KRAS mutation
|
Oral Cancer
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
PD-L1 overexpression
|
Oral Cancer
|
PD-L1 overexpression
|
Oral Cancer
|
nivolumab + MGCD516 Sensitive: C3 – Early Trials
|
nivolumab + MGCD516 Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Oral Cancer
|
PD-L1 overexpression
|
Oral Cancer
|
olaparib Sensitive: C3 – Early Trials
|
olaparib Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Oral Cancer
|
PD-L1 overexpression
|
Oral Cancer
|
pazopanib Sensitive: C3 – Early Trials
|
pazopanib Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Oral Cancer
|
PD-L1 overexpression
|
Oral Cancer
|
paclitaxel Sensitive: C3 – Early Trials
|
paclitaxel Sensitive: C3 – Early Trials
|
PD-L1 overexpression
|
Oral Cancer
|
PD-L1 overexpression
|
Oral Cancer
|
docetaxel Sensitive: C3 – Early Trials
|
docetaxel Sensitive: C3 – Early Trials
|
CHEK2 mutation
|
Tongue Carcinoma
|
CHEK2 mutation
|
Tongue Carcinoma
|
ABT-888 + M6620 Sensitive: C4 – Case Studies
|
ABT-888 + M6620 Sensitive: C4 – Case Studies
|
FGFR2 P253R
|
Tongue Carcinoma
|
FGFR2 P253R
|
Tongue Carcinoma
|
cetuximab Sensitive: C4 – Case Studies
|
cetuximab Sensitive: C4 – Case Studies
|
FGFR2 P253R
|
Tongue Carcinoma
|
FGFR2 P253R
|
Tongue Carcinoma
|
pazopanib Sensitive: C4 – Case Studies
|
pazopanib Sensitive: C4 – Case Studies
|
PD-L1 overexpression
|
Oral Cancer
|
PD-L1 overexpression
|
Oral Cancer
|
nivolumab + nimotuzumab Sensitive: C4 – Case Studies
|
nivolumab + nimotuzumab Sensitive: C4 – Case Studies
|
PD-L1 overexpression
|
Oral Cancer
|
PD-L1 overexpression
|
Oral Cancer
|
pembrolizumab Sensitive: C4 – Case Studies
|
pembrolizumab Sensitive: C4 – Case Studies
|
CMTM6 overexpression
|
Oral Cancer
|
CMTM6 overexpression
|
Oral Cancer
|
cisplatin Resistant: D – Preclinical
|
cisplatin Resistant: D – Preclinical
|
EGF expression
|
Tongue Carcinoma
|
EGF expression
|
Tongue Carcinoma
|
cetuximab Resistant: D – Preclinical
|
cetuximab Resistant: D – Preclinical
|
PIK3CA Q546R
|
Oral Cancer
|
PIK3CA Q546R
|
Oral Cancer
|
palbociclib Resistant: D – Preclinical
|
palbociclib Resistant: D – Preclinical
|
PIK3CA H1047L
|
Oral Cancer
|
PIK3CA H1047L
|
Oral Cancer
|
palbociclib Resistant: D – Preclinical
|
palbociclib Resistant: D – Preclinical
|
miR-155 overexpression
|
Oral Cancer
|
miR-155 overexpression
|
Oral Cancer
|
cisplatin Resistant: D – Preclinical
|
cisplatin Resistant: D – Preclinical
|
FOXO3 underexpression
|
Oral Cancer
|
FOXO3 underexpression
|
Oral Cancer
|
cisplatin Resistant: D – Preclinical
|
cisplatin Resistant: D – Preclinical
|
EGFR amplification
|
Oral Cancer
|
EGFR amplification
|
Oral Cancer
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
EGFR amplification
|
Oral Cancer
|
EGFR amplification
|
Oral Cancer
|
AZD0530 Sensitive: D – Preclinical
|
AZD0530 Sensitive: D – Preclinical
|
EGFR amplification
|
Oral Cancer
|
EGFR amplification
|
Oral Cancer
|
lapatinib Sensitive: D – Preclinical
|
lapatinib Sensitive: D – Preclinical
|
EGFR amplification
|
Oral Cancer
|
EGFR amplification
|
Oral Cancer
|
gefitinib Sensitive: D – Preclinical
|
gefitinib Sensitive: D – Preclinical
|
EGFR amplification
|
Oral Cancer
|
EGFR amplification
|
Oral Cancer
|
erlotinib Sensitive: D – Preclinical
|
erlotinib Sensitive: D – Preclinical
|
EGFR amplification
|
Oral Cancer
|
EGFR amplification
|
Oral Cancer
|
cetuximab Sensitive: D – Preclinical
|
cetuximab Sensitive: D – Preclinical
|
GDF15 overexpression
|
Oral Cancer
|
GDF15 overexpression
|
Oral Cancer
|
CI-1033 Sensitive: D – Preclinical
|
CI-1033 Sensitive: D – Preclinical
|
MME overexpression
|
Oral Cancer
|
MME overexpression
|
Oral Cancer
|
cisplatin Resistant: D – Preclinical
|
cisplatin Resistant: D – Preclinical
|
HPRT1 overexpression
|
Oral Cancer
|
HPRT1 overexpression
|
Oral Cancer
|
cisplatin Resistant: D – Preclinical
|
cisplatin Resistant: D – Preclinical
|
